Invizius

Invizius is an Edinburgh biotechnology company developing treatments intended to reduce inflammation during procedures that circulate blood outside the body. It was spun out from University of Edinburgh research and operates through Invizius Limited (SC586903). The company's development work focuses on the body's complement system.

Its H-Guard technology is designed to coat medical circuits used for treatments such as dialysis. Contact between blood and artificial surfaces can trigger inflammatory responses, and the product is intended to reduce that reaction. The company has also discussed potential applications in other extracorporeal procedures.

Invizius has raised investment to support research, development and clinical evaluation. The technology remains subject to the evidence and regulatory steps relevant to a medical product, so the listing should not present it as an established treatment. The company's Edinburgh base provides its Scottish business connection.